New support services created to help consumers and patients take charge of
their fertility
ROCKLAND, Mass., Aug. 10 /PRNewswire/ -- Fertility LifeLines, a free and
confidential educational service from Serono, Inc., has enhanced its services
to provide added value and support to the estimated six million Americans who
suffer from infertility, many of whom never seek treatment. Fertility
LifeLines is available at 1-866-LETS-TRY (1-866-538-7879).
Callers to Fertility LifeLines can now receive special benefits and access
to potential savings on all Serono fertility products. The new benefits
include a customized information kit with suggested questions to ask a doctor
and a free subscription to Conceive, the leading lifestyle magazine written
specifically for women trying to get pregnant. Fertility LifeLines callers
can also access pharmacy services from Freedom Drug(TM), the nation's largest
fertility pharmacy, including pharmacists available 24/7 and free priority
overnight shipping on all orders.
"Many of our readers have questions and concerns regarding their
fertility, especially ways to pay for potential treatments," says Kim Hahn,
Founder and Publishing Director of Conceive and former IVF patient. "A phone
call to Fertility LifeLines provides access to information and support that
give people options for moving forward and taking the next step in their
journey to conceive."
Fertility LifeLines provides callers with information on infertility, a
summary of their infertility insurance coverage, emotional support through
compassionate listening and support for Serono fertility products including
one-on-one injection training over the phone and online. It is staffed with
fertility nurses, insurance specialists and patient advocates who are
specially trained to respond to the needs of individual callers.
"People who experience infertility often feel alone and overwhelmed, and
it's important for them to have resources like Fertility LifeLines that they
can turn to," says Dr. Kaylen Silverberg, Medical Director at Texas Fertility
Center. "Fertility LifeLines provides a level of personal service that can
benefit patients as they work with their healthcare providers to manage the
many concerns they face with infertility."
Fertility LifeLines is available Monday through Friday from 8 am to
midnight ET and Saturday and Sunday from 8 am to 6 pm with 24-hour access to
fertility nurses and Freedom Drug pharmacists seven days a week. For more
information, call toll-free 1-866-LETS-TRY (1-866-538-7879) or visit
http://www.fertilitylifelines.com.
About Infertility
Infertility is defined as the inability to achieve pregnancy after one
year of regular, unprotected intercourse (six months if the woman is over 35).
It affects about 6.1 million Americans, which represents about 10 percent of
couples in their childbearing years. The majority of patients who complete
treatment succeed in having a child.
About Fertility LifeLines
Fertility LifeLines is a free and confidential educational service
provided by Serono, Inc., the leader in fertility health. Available toll-free
at 1-866-LETS-TRY (1-866-538-7879), it offers a single destination for 24/7
information and support to people with concerns about infertility, including
access to special benefits and potential savings on all Serono fertility
products. Staffed with fertility nurses, insurance specialists and patient
advocates, Fertility LifeLines is available Monday to Friday from 8 am to
midnight ET and Saturday and Sunday from 8 am to 6 pm with 24-hour access to
fertility nurses and Freedom Drug pharmacists. Fertility LifeLines is not
meant to substitute for the advice provided by a medical professional.
Callers should always consult a healthcare provider if they have health
concerns. For more information about Fertility LifeLines, call toll-free 1-
866-LETS-TRY (1-866-538-7879) or visit http://www.fertilitylifelines.com.
About Serono, Inc. and Fertility
Serono, Inc., a subsidiary of Serono S.A., is a leader in fertility
health, dedicated to developing patient-friendly, innovative products that
help people build families. It is the only company to offer a full portfolio
of fertility medications for every stage of the reproductive cycle and
recombinant versions of three hormones used in the treatment of infertility,
including the Gonal-f(R) RFF Pen (follitropin alfa injection).
About Serono S.A.
Serono is a global biotechnology leader. The Company has eight
biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) Prefilled
Syringe/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R). In
addition to being the worldwide leader in reproductive health, Serono has
strong market positions in neurology, metabolism and growth and has recently
entered the psoriasis area. The Company's research programs are focused on
growing these businesses and on establishing new therapeutic areas, including
oncology. Currently, there are approximately 25 ongoing development projects.
In 2004, Serono achieved worldwide revenues of US$2,458.1 million, and a
net income of US$494.2 million, making it the third largest biotech company in
the world. Its products are sold in over 90 countries. Bearer shares of
Serono S.A., the holding company, are traded on the virt-x (SEO) and its
American Depositary Shares are traded on the New York Stock Exchange (SRA).
Package inserts for Serono's US marketed products are available at
http://www.seronousa.com or by calling 1-888-275-7376.
Some of the statements in this press release are forward looking. Such
statements are inherently subject to known and unknown risks, uncertainties
and other factors that may cause actual results, performance or achievements
of Serono S.A. and affiliates to be materially different from those expected
or anticipated in the forward-looking statements. Forward-looking statements
are based on Serono's current expectations and assumptions, which may be
affected by a number of factors, including those discussed in this press
release and more fully described in Serono's Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission on March 16, 2005. These
factors include any failure or delay in Serono's ability to develop new
products, any failure to receive anticipated regulatory approvals, any
problems in commercializing current products as a result of competition or
other factors, our ability to obtain reimbursement coverage for our products,
the outcome of government investigations and litigation and government
regulations limiting our ability to sell our products. Serono has no
responsibility to update the forward-looking statements contained in this
press release to reflect events or circumstances occurring after the date of
this press release.
Certain statements included in this press release, which are not
historical facts, are forward-looking statements. Such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
represent our expectations or beliefs and involve certain risks and
uncertainties, including those described in our public filings with the United
States Securities and Exchange Commission; also including, but not limited to,
changes in interest rates, competitive pressures, changes in customer mix,
changes in third party reimbursement rates, financial stability of major
customers, changes in government regulations or the interpretation of these
regulations, changes in supplier relationships, growth opportunities, cost
savings, revenue enhancements, synergies and other benefits anticipated from
acquisition transactions, difficulties relative to integrating acquired
businesses, the accounting and tax treatment of acquisitions, and asserted and
unasserted claims, which could cause actual results to differ from those in
the forward-looking statements. The forward-looking statements by their
nature involve substantial risks and uncertainties, certain of which are
beyond our control, and actual results may differ materially depending on a
variety of important factors. You are cautioned not to place undue reliance
on these forward-looking statements that speak only as of the date herein.
For more information, please contact:
Serono, Inc., Rockland, MA
Media Relations:
Dana Jessup
Tel. +1 781 681 2443
Fax: +1 781 681 2935
http://www.seronousa.com
SOURCE Serono, Inc.
 back to top
Related links:
http://www.fertilitylifelines.com
http://www.seronousa.com
CONTACT:
Dana Jessup of Serono, Inc., +1-781-681-2443
|
